4516 日本新薬

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	170,771	35,496	20.8%	-	-	29,721	17.4%	441.00	6.6%	0.1%	0.0%	-8.7%
2025/03	4Q	160,232	35,450	22.1%	-	-	32,558	20.3%	483.40	8.1%	6.5%	0.0%	25.9%
2024/03	4Q	148,255	33,295	22.5%	-	-	25,851	17.4%	383.82	2.8%	10.8%	0.0%	13.3%
2023/03	4Q	144,175	30,049	20.8%	-	-	22,812	15.8%	338.70	4.8%	6.2%	-100.0%	-1.0%
2022/03	4Q	137,547	28,299	20.6%	29,773	21.6%	23,044	16.8%	342.14	12.8%	8.3%	11.3%	11.3%
2022/03	4Q	137,484	32,948	24.0%	-	-	24,986	18.2%	370.97	12.8%	26.1%	-100.0%	20.7%
2021/03	4Q	121,885	26,134	21.4%	26,760	22.0%	20,702	17.0%	307.37	4.5%	20.6%	19.2%	22.7%
2020/03	4Q	116,637	21,668	18.6%	22,442	19.2%	16,866	14.5%	250.42	1.7%	5.0%	4.2%	3.5%
2019/03	4Q	114,716	20,644	18.0%	21,540	18.8%	16,302	14.2%	242.04	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	170,771	35,496	20.8%	-	-	29,721	17.4%	441.00	6.6%	0.1%	0.0%	-8.7%
2025/03	4Q	160,232	35,450	22.1%	-	-	32,558	20.3%	483.40	8.1%	6.5%	0.0%	25.9%
2024/03	4Q	148,255	33,295	22.5%	-	-	25,851	17.4%	383.82	2.8%	10.8%	0.0%	13.3%
2023/03	4Q	144,175	30,049	20.8%	-	-	22,812	15.8%	338.70	4.9%	-8.8%	0.0%	-8.7%
2022/03	4Q	137,484	32,948	24.0%	-	-	24,986	18.2%	370.97	12.8%	26.1%	-100.0%	20.7%
2022/03	4Q	137,547	28,299	20.6%	29,773	21.6%	23,044	16.8%	342.14	12.8%	8.3%	11.3%	11.3%
2021/03	4Q	121,885	26,134	21.4%	26,760	22.0%	20,702	17.0%	307.37	4.5%	20.6%	19.2%	22.7%
2020/03	4Q	116,637	21,668	18.6%	22,442	19.2%	16,866	14.5%	250.42	1.7%	5.0%	4.2%	3.5%
2019/03	4Q	114,716	20,644	18.0%	21,540	18.8%	16,302	14.2%	242.04	-	-	-	-